178 related articles for article (PubMed ID: 38398485)
21. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
[TBL] [Abstract][Full Text] [Related]
22. Advances in the long-term treatment of neuromyelitis optica spectrum disorder.
Anderson M; Levy M
J Cent Nerv Syst Dis; 2024; 16():11795735241231094. PubMed ID: 38312734
[TBL] [Abstract][Full Text] [Related]
23. Spinal cord atrophy in neuromyelitis optica spectrum disorders.
Wang Y; Wang Y; Tan S; Lu Z
Mult Scler Relat Disord; 2016 Jul; 8():9-10. PubMed ID: 27456868
[TBL] [Abstract][Full Text] [Related]
24. Short transverse myelitis in Chinese patients with neuromyelitis optica spectrum disorders.
Hu H; You X; Ye J
Mult Scler Relat Disord; 2018 Apr; 21():78-83. PubMed ID: 29499441
[TBL] [Abstract][Full Text] [Related]
25. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder.
Min W; Zhang L; Wang S; Xue M; Guo C; Zhu M
Mult Scler Relat Disord; 2023 Feb; 70():104517. PubMed ID: 36708681
[TBL] [Abstract][Full Text] [Related]
26. Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19.
Chen S; Fan XR; He S; Zhang JW; Li SJ
Neurol Sci; 2021 Sep; 42(9):3537-3539. PubMed ID: 34189662
[TBL] [Abstract][Full Text] [Related]
27. Elucidating distinct clinico-radiologic signatures in the borderland between neuromyelitis optica and multiple sclerosis.
Juryńczyk M; Klimiec-Moskal E; Kong Y; Hurley S; Messina S; Yeo T; Jenkinson M; Leite MI; Palace J
J Neurol; 2022 Jan; 269(1):269-279. PubMed ID: 34043042
[TBL] [Abstract][Full Text] [Related]
28. Multicentric clinical and epidemiological comparison of neuromyelitis optica spectrum disorder with multiple sclerosis from India.
Gupta S; Rehani V; Acharya R; Purohit P; Anadure R; Ahmad F; Soni R; Gupta A; Hiremath R
Mult Scler Relat Disord; 2021 Jan; 47():102616. PubMed ID: 33166808
[TBL] [Abstract][Full Text] [Related]
29. Neuromyelitis Optica Spectrum Disorder: Clinical Burden and Cost of Relapses and Disease-Related Care in US Clinical Practice.
Royston M; Kielhorn A; Weycker D; Shaff M; Houde L; Tanvir I; Bhattacharyya S; Levy M
Neurol Ther; 2021 Dec; 10(2):767-783. PubMed ID: 34046846
[TBL] [Abstract][Full Text] [Related]
30. The risk factors of neuropathic pain in neuromyelitis optica spectrum disorder: a retrospective case-cohort study.
Li X; Xu H; Zheng Z; Ouyang H; Chen G; Lou Z; Chen H; Zhang J; Zhan Y; Mao H; Zhang C; Zhao M; Zhao Y
BMC Neurol; 2022 Aug; 22(1):304. PubMed ID: 35986246
[TBL] [Abstract][Full Text] [Related]
31. Safety of SARS-CoV2 vaccination and COVID-19 short-term outcome in pediatric acquired demyelinating disorders of central nervous system: A single center experience.
Monte G; Papetti L; Ferilli MAN; Ursitti F; Moavero R; Sforza G; Panella E; Tarantino S; Checchi MP; Vigevano F; Palma P; Valeriani M
Front Immunol; 2023; 14():1106472. PubMed ID: 36761740
[TBL] [Abstract][Full Text] [Related]
32. Visualizing the Central Nervous System: Imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.
Kuchling J; Paul F
Front Neurol; 2020; 11():450. PubMed ID: 32625158
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
Ma J; Yu H; Wang H; Zhang X; Feng K
J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
[TBL] [Abstract][Full Text] [Related]
34. Neuromyelitis Optica Spectrum Disorders Mimicking Multiple Brain Tumors.
Park SH; Hwang JH
Brain Tumor Res Treat; 2021 Apr; 9(1):35-39. PubMed ID: 33913271
[TBL] [Abstract][Full Text] [Related]
35. Very late onset neuromyelitis optica spectrum disorders.
Nakahara K; Nakane S; Nagaishi A; Narita T; Matsuo H; Ando Y
Eur J Neurol; 2021 Aug; 28(8):2574-2581. PubMed ID: 33960076
[TBL] [Abstract][Full Text] [Related]
36. Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders.
Zalewski NL; Morris PP; Weinshenker BG; Lucchinetti CF; Guo Y; Pittock SJ; Krecke KN; Kaufmann TJ; Wingerchuk DM; Kumar N; Flanagan EP
J Neurol Neurosurg Psychiatry; 2017 Mar; 88(3):218-225. PubMed ID: 27913626
[TBL] [Abstract][Full Text] [Related]
37. Inebilizumab for treatment of neuromyelitis optica spectrum disorder.
J Tullman M; Zabeti A; Vuocolo S; Dinh Q
Neurodegener Dis Manag; 2021 Oct; 11(5):341-352. PubMed ID: 34486379
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD.
Kim S; Seok HY
Neurol Sci; 2023 Jun; 44(6):1841-1848. PubMed ID: 36781562
[TBL] [Abstract][Full Text] [Related]
39. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
Kümpfel T; Giglhuber K; Aktas O; Ayzenberg I; Bellmann-Strobl J; Häußler V; Havla J; Hellwig K; Hümmert MW; Jarius S; Kleiter I; Klotz L; Krumbholz M; Paul F; Ringelstein M; Ruprecht K; Senel M; Stellmann JP; Bergh FT; Trebst C; Tumani H; Warnke C; Wildemann B; Berthele A;
J Neurol; 2024 Jan; 271(1):141-176. PubMed ID: 37676297
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
